Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
Immune checkpoint inhibitors (ICIs), including antibodies that target programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA4), represent some of the most important breakthroughs in new drug development for oncology therapy from the past...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/2/294 |
| _version_ | 1797495358953095168 |
|---|---|
| author | Ching-Hung Hsieh Cheng-Zhe Jian Liang-In Lin Guan-Sian Low Ping-Yun Ou Chiun Hsu Da-Liang Ou |
| author_facet | Ching-Hung Hsieh Cheng-Zhe Jian Liang-In Lin Guan-Sian Low Ping-Yun Ou Chiun Hsu Da-Liang Ou |
| author_sort | Ching-Hung Hsieh |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs), including antibodies that target programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA4), represent some of the most important breakthroughs in new drug development for oncology therapy from the past decade. CXC chemokine ligand 13 (CXCL13) exclusively binds CXC chemokine receptor type 5 (CXCR5), which plays a critical role in immune cell recruitment and activation and the regulation of the adaptive immune response. CXCL13 is a key molecular determinant of the formation of tertiary lymphoid structures (TLSs), which are organized aggregates of T, B, and dendritic cells that participate in the adaptive antitumor immune response. CXCL13 may also serve as a prognostic and predictive factor, and the role played by CXCL13 in some ICI-responsive tumor types has gained intense interest. This review discusses how CXCL13/CXCR5 signaling modulates cancer and immune cells to promote lymphocyte infiltration, activation by tumor antigens, and differentiation to increase the antitumor immune response. We also summarize recent preclinical and clinical evidence regarding the ICI-therapeutic implications of targeting the CXCL13/CXCR5 axis and discuss the potential role of this signaling pathway in cancer immunotherapy. |
| first_indexed | 2024-03-10T01:47:41Z |
| format | Article |
| id | doaj.art-fce4a1f6430642e5b276ecb456f6615d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:47:41Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-fce4a1f6430642e5b276ecb456f6615d2023-11-23T13:12:34ZengMDPI AGCancers2072-66942022-01-0114229410.3390/cancers14020294Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in CancerChing-Hung Hsieh0Cheng-Zhe Jian1Liang-In Lin2Guan-Sian Low3Ping-Yun Ou4Chiun Hsu5Da-Liang Ou6Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City 10048, TaiwanGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City 10051, TaiwanDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City 10048, TaiwanDepartment of Animal Science and Technology, National Taiwan University, Taipei City 10672, TaiwanInstitute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei City 11221, TaiwanGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City 10051, TaiwanGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City 10051, TaiwanImmune checkpoint inhibitors (ICIs), including antibodies that target programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA4), represent some of the most important breakthroughs in new drug development for oncology therapy from the past decade. CXC chemokine ligand 13 (CXCL13) exclusively binds CXC chemokine receptor type 5 (CXCR5), which plays a critical role in immune cell recruitment and activation and the regulation of the adaptive immune response. CXCL13 is a key molecular determinant of the formation of tertiary lymphoid structures (TLSs), which are organized aggregates of T, B, and dendritic cells that participate in the adaptive antitumor immune response. CXCL13 may also serve as a prognostic and predictive factor, and the role played by CXCL13 in some ICI-responsive tumor types has gained intense interest. This review discusses how CXCL13/CXCR5 signaling modulates cancer and immune cells to promote lymphocyte infiltration, activation by tumor antigens, and differentiation to increase the antitumor immune response. We also summarize recent preclinical and clinical evidence regarding the ICI-therapeutic implications of targeting the CXCL13/CXCR5 axis and discuss the potential role of this signaling pathway in cancer immunotherapy.https://www.mdpi.com/2072-6694/14/2/294immune checkpoint inhibitorCXCL13/CXCR5tertiary lymphoid structure |
| spellingShingle | Ching-Hung Hsieh Cheng-Zhe Jian Liang-In Lin Guan-Sian Low Ping-Yun Ou Chiun Hsu Da-Liang Ou Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer Cancers immune checkpoint inhibitor CXCL13/CXCR5 tertiary lymphoid structure |
| title | Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer |
| title_full | Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer |
| title_fullStr | Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer |
| title_full_unstemmed | Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer |
| title_short | Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer |
| title_sort | potential role of cxcl13 cxcr5 signaling in immune checkpoint inhibitor treatment in cancer |
| topic | immune checkpoint inhibitor CXCL13/CXCR5 tertiary lymphoid structure |
| url | https://www.mdpi.com/2072-6694/14/2/294 |
| work_keys_str_mv | AT chinghunghsieh potentialroleofcxcl13cxcr5signalinginimmunecheckpointinhibitortreatmentincancer AT chengzhejian potentialroleofcxcl13cxcr5signalinginimmunecheckpointinhibitortreatmentincancer AT lianginlin potentialroleofcxcl13cxcr5signalinginimmunecheckpointinhibitortreatmentincancer AT guansianlow potentialroleofcxcl13cxcr5signalinginimmunecheckpointinhibitortreatmentincancer AT pingyunou potentialroleofcxcl13cxcr5signalinginimmunecheckpointinhibitortreatmentincancer AT chiunhsu potentialroleofcxcl13cxcr5signalinginimmunecheckpointinhibitortreatmentincancer AT daliangou potentialroleofcxcl13cxcr5signalinginimmunecheckpointinhibitortreatmentincancer |